

Haematologica
HAEMATOL/2015/124818
Version 3

Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial

Disclosures: MVM has received honoraria and participated on advisory boards of Janssen. JSM has received honoraria and participated on advisory boards of Janssen, Millenium, Celgene, Novartis, BMS, MSD, Onyx. AAM has participated on advisory boards of Janssen, Celgene and Amgen. LR has received honoraria and participated on advisory boards of Janssen. FA has received honoraria and participated on advisory boards of Janssen. JM has received honoraria from Janssen. JJJ has received honoraria and participated on advisory boards of Janssen. JB has received honoraria and participated on advisory boards of Janssen, Celgene, Onyx, Binding Site, Amgen. AP has received honoraria and participated on advisory boards of Janssen. The rest of authors declare no conflict of interest

Contributions: MVM and JSM were principal investigators and were involved in the original conception and design of the study, writing the protocol, analysing and interpreting data, and writing the manuscript. All authors were involved in patient recruitment, and reviewed and approved the paper.